Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that Abraxane (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the TGA for the first-line treatment of metastatic pancreatic cancer. 

The TGA approved indication is: Abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

For more details, go to: http://www.specialisedtherapeutics.com.au/index.php?q=mar-2014-sta-receives-tga-approval-for-abraxan...